Dario Ponce de Leon

TL;DR: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo, and the proportional odds of having a worse score on the eight-level ordinal scale with tofacinib, as compared with placebo.

TL;DR: The results of these surveys highlight the impact of RA on patients, and a discrepancy between patient and physician views on communication, and further research is needed on improving patient–physician dialogue, shared goal-setting, and treatment planning.

TL;DR: Data from published studies reporting demographics and clinical aspects of UC in Latin America are reviewed to further understand epidemiology and disease burden and to influence therapeutic approaches and the development of strategies to improve healthcare access and patient outcomes.

TL;DR: Across P1/2/3/4/long-term extension studies, incidence rates for ILD events were 0.18 following tofacitinib treatment, and ILD Events were associated with known risk factors for I LD in RA.

TL;DR: Patients with rheumatoid arthritis may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making.